Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > FORCE Weighs In on Prostate Cancer Screening Guidelines

| More

Newsflash

7/15/2018
We joined the Friends of the Cancer Policy Institute coalition in submitting comments on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

6/20/2018
FORCE, along with over two dozen orgs, issued a statement on the final rule permitting expansion of association health plans. Read Statement...

6/1/2018
FORCE staff are attending the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

5/9/18
We joined 80 patient advocacy, medical, and industry orgs in urging Congress to enact legislation to modernize FDA oversight of clinical laboratory diagnostics. Read letter...

5/8/2018
FORCE, along with over 100 other organizations, is advocating for continued funding of DoD research programs. Read our letters to Senate and House leaders.

FORCE Weighs In on Prostate Cancer Screening Guidelines

Screening & Prevention

Overview

In May 2017, FORCE submitted comments on the U.S. Preventive Services Task Force (USPSTF) Draft Recommendation Statement and Evidence Review for Prostate Cancer Screening. The USPSTF is a panel of experts in prevention and evidence-based medicine which reviews of and develops recommendations on the effectiveness of a broad range of preventive services. Once finalized, these guidelines are utilized by health care providers to determine appropriate screening and care, and to inform insurance coverage decisions on specific preventive services.

The Affordable Care Act stipulates that any preventive service receiving a USPSTF rating of “A” or “B” must be covered by most health plans with no copay or cost-sharing for the patient. Consequently, these guidelines impact access to care for many members of the hereditary cancer community.

Current guidelines give a grade "D" to the use of prostate-specific antigen (PSA) testing to screen for prostate cancer. The new draft guidelines give a "C" to PSA testing.  This means that the USPSTF recommends "selectively offering or providing this service to individual patients based on professional judgment and patient preferences." This is an improvement over the current prostate cancer screening guidelines released in May 2012, which recommended against the use of PSA testing for early detection of prostate cancer. We are concerned, however, that a grade "C" may negatively affect health care coverage for cancer screening of men with BRCA or other inherited genetic mutations which predispose them to prostate cancer.

It is important to differentiate between "average risk" men and those who may be at increased risk of cancer. FORCE suggested that the Task Force review the data, extend the evaluation and assign a grade “B” for PSA testing in high-risk men. See our submitted comments to learn more about our concerns and proposed revisions to the draft guidelines.

For more history on this issue, refer to information about the 2012 PSA Screening Guidelines posted on our website.

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered